Liquidia Shares Surge 25% Following United Therapeutics Litigation Settlement

Key Facts

1Liquidia shares surged 25% to $33.47 following a settlement of all six pending lawsuits with United Therapeutics.

2The settlement ends years of patent and antitrust disputes regarding the YUTREPIA treatment for pulmonary arterial hypertension.

Liquidia Corporation shares surged 25% to $33.47 following a settlement of all six pending lawsuits with United Therapeutics. Proactive Investors reported that the agreement concludes years of patent and antitrust disputes regarding the YUTREPIA treatment for pulmonary arterial hypertension.

LQDA closed at $26.81 on October 13, 2026, while UTHR closed at $543.4 on the same date. Under the terms of the settlement, Liquidia will pay $380.7 million in installments through April 2027, with management expecting to meet these obligations using existing cash reserves and revenue from YUTREPIA sales.